Peptoniphilus ivorii

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Peptoniphilus ivorii is a Gram-positive, non-spore-forming, strictly anaerobic, non-motile, coccus bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. The DNA G+C content is 29%. Peptoniphilus ivorii is probably a rare gut coloniser. (Ezaki2001; Murdoch1997)



  • This organism has been recovered from a leg ulcer. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. A possible gut commensal.
    • QUIRKS
  • Carbohydrates are not fermented.
    • GENERAL CHARACTERISTICS (Ezaki2001); (Murdoch1997);
    Character Response
  • Active enzymes:
  • Pro arylamidase;
  • ±
  • Strain-dependent active enzymes:
  • catalase;
    • SPECIAL FEATURES (Ezaki2001); (Murdoch1997);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (minor); propionate (minor); butyrate; isobutyrate (minor); isovalerate;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • Haemolysis:
  • absent
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Tyrrell2012); (Goldstein2000);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ertapenem; imipenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin;
  • Macrolides:
  • erythromycin;
  • Tetracyclines:
  • doxycycline; minocycline;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; linezolid;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Tissierellia Order:  Tissierellales Family:  Peptoniphilaceae Genus:  Peptoniphilus Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus
    Health:  Unknown
    Source:  a leg ulcer
    DNA G+C(%):  29
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Glucose:  neg Mannose:  neg Ribose:  neg Cellubiose:  neg Lactose:  neg Maltose:  neg Sucrose:  neg Trehalose:  neg Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  d Urease:  neg Coagulase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg ArgDH:  neg ArgAA:  neg HisAA:  neg LeuAA:  neg ProAA:  + PheAA:  neg PyrogluAA:  neg AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  minor(+) Propionate:  minor(+) Butyrate:  + Isobutyrate:  minor(+) Isovalerate:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(0.19–0.38)
    ampicillin:  S(MIC50): 0.03, MIC90: 0.25, RNG: (0.03–>8)
    penicillin:  S(0.094–0.125)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.25, RNG: (≤0.015–1)
    piper-taz:  S(MIC50): 0.03, MIC90: 0.5, RNG: (0.03–16)
    ertapenem:  S(0.06/0.25)
    imipenem:  S(MIC50): 0.03, MIC90: 0.06, RNG: (0.03–2)
    cefoxitin:  S(0.25–0.5)
    azithromycin:  Var(MIC50): 0.5, MIC90: >32, RNG: (0.25–>32)
    erythromycin:  S(MIC50): 0.25, MIC90: 0.128, RNG: (0.06–.128)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–2)
    levofloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125–>8)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–0.5)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 4, RNG: (0.06–16)
    minocycline:  S(MIC50): 0.125, MIC90: 8, RNG: (0.03–8)
    tetracycline:  Var(MIC50): 0.5, MIC90: 16, RNG: (0.125–32)
    vancomycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–1)
    chloramphenicol:  S(0.75–1.0)
    metronidazole:  S(MIC50): 0.25, MIC90: 1, RNG: (0.03–2)
    clindamycin:  S(0.016–0.125)
    daptomycin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.03–1)

    References

    SPECIFIC REFERENCES FOR PEPTONIPHILUS IVORII
  • Ezaki2001 - Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov. and Gallicola gen. nov. for members of the genus Peptostreptococcus.
  • Murdoch1997 - Description of Three New Species of the Genus Peptostreptococcus from Human Clinical Specimens: Peptostreptococcus harei sp. nov., Peptostreptococcus ivorii sp. nov., and Peptostreptococcus octavius sp. nov.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PEPTONIPHILUS IVORII
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • ...............................
    • Added: March 18, 2022